VAXX vs. BNOX, TRVN, CANF, EFTR, OGEN, VIRI, OBSV, CYCN, HEPA, and CVKD
Should you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Bionomics (BNOX), Trevena (TRVN), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Oragenics (OGEN), Virios Therapeutics (VIRI), ObsEva (OBSV), Cyclerion Therapeutics (CYCN), Hepion Pharmaceuticals (HEPA), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Vaxxinity has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, Bionomics has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
Bionomics' return on equity of 0.00% beat Vaxxinity's return on equity.
Vaxxinity presently has a consensus price target of $7.00, indicating a potential upside of 12,862.96%. Bionomics has a consensus price target of $9.00, indicating a potential upside of 865.67%. Given Vaxxinity's higher probable upside, equities research analysts plainly believe Vaxxinity is more favorable than Bionomics.
Bionomics has lower revenue, but higher earnings than Vaxxinity.
Bionomics received 11 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 72.73% of users gave Bionomics an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
83.0% of Vaxxinity shares are held by institutional investors. Comparatively, 15.9% of Bionomics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 1.5% of Bionomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Vaxxinity and Vaxxinity both had 2 articles in the media. Bionomics' average media sentiment score of 1.58 beat Vaxxinity's score of 1.44 indicating that Bionomics is being referred to more favorably in the news media.
Summary
Bionomics beats Vaxxinity on 8 of the 13 factors compared between the two stocks.
Get Vaxxinity News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaxxinity Competitors List
Related Companies and Tools
